{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:07:44Z","timestamp":1790233664056,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ygyno.2010.09.017","type":"journal-article","created":{"date-parts":[[2010,11,8]],"date-time":"2010-11-08T09:05:41Z","timestamp":1289207141000},"page":"128-134","source":"Crossref","is-referenced-by-count":26,"title":["Mullerian Inhibiting Substance inhibits invasion and migration of epithelial cancer cell lines"],"prefix":"10.1016","volume":"120","author":[{"given":"Henry L.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Pieretti-Vanmarcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Nicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"MacLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Donahoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.09.017_bb0005","first-page":"3488","article-title":"Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian Inhibiting Substance (MIS) type II receptor, bind, and are responsive to MIS","volume":"7","author":"Masiakos","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0010","doi-asserted-by":"crossref","first-page":"28371","DOI":"10.1074\/jbc.M004554200","article-title":"Mullerian Inhibiting Substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway","volume":"275","author":"Segev","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1073\/pnas.221599298","article-title":"Mullerian Inhibiting Substance regulates NF-kappa B signaling in the prostate in vitro and in vivo","volume":"99","author":"Segev","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0020","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.0607959103","article-title":"Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer","volume":"103","author":"Pieretti-Vanmarcke","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/er.22.5.657","article-title":"Mullerian Inhibiting Substance: an instructive developmental hormone with diagnostic and possible therapeutic applications","volume":"22","author":"Teixeira","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0012-1606(82)90146-4","article-title":"Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression","volume":"92","author":"Hayashi","year":"1982","journal-title":"Dev Biol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/dbio.1995.1123","article-title":"DiI analysis of cell migration during Mullerian duct regression","volume":"169","author":"Austin","year":"1995","journal-title":"Dev Biol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0040","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1242\/dev.02383","article-title":"Mullerian Inhibiting Substance regulates its receptor\/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression","volume":"133","author":"Zhan","year":"2006","journal-title":"Development"},{"issue":"2","key":"10.1016\/j.ygyno.2010.09.017_bb0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ydbio.2008.10.027","article-title":"Cell migration and activated PI3K\/AKT-directed elongation in the developing rat M\u00fcllerian duct","volume":"325","author":"Fujino","year":"2009","journal-title":"Dev Biol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1242\/dev.120.1.189","article-title":"A novel member of the transmembrane serine\/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Mullerian duct","volume":"120","author":"Baarends","year":"1994","journal-title":"Development"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0055","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.8.8.1006","article-title":"Cloning, expression, and alternative splicing of the receptor for anit-Mullerian hormone","volume":"8","author":"DiClemente","year":"1994","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1210\/en.137.1.160","article-title":"Developmental expression of a candidate Mullerian Inhibiting Substance type II receptor","volume":"137","author":"Teixeira","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1006\/bbrc.1997.7224","article-title":"Sequence, genomic organization and chromosomal location of the mouse Mullerian Inhibiting Substance type II receptor gene","volume":"237","author":"Mishina","year":"1997","journal-title":"Biochem Res Commun"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ng1295-382","article-title":"Insensitivity to anti-Mullerian hormone due to a mutation in the human anti-Mullerian hormone receptor","volume":"11","author":"Imbeaud","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1210\/en.131.3.1481","article-title":"Effect of human recombinant Mullerian Inhibiting Substance on isolated epithelial and mesenchymal cells during Mullerian duct regression in the rat","volume":"131","author":"Tsuji","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/humupd\/dmi014","article-title":"AMH and AMH receptor defects in persistent Mullerian duct syndrome","volume":"11","author":"Josso","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/bdra.10091","article-title":"Persistent Mullerian duct syndrome with a deletion and a novel splicing Mutation in the MIS type II receptor","volume":"67","author":"Hoshiya","year":"2003","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0090","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1210\/en.140.10.4732","article-title":"M\u00fcllerian-inhibiting substance regulates androgen synthesis at the transcriptional level","volume":"140","author":"Teixeira","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0095","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/j.1939-4640.2001.tb02577.x","article-title":"M\u00fcllerian inhibiting substance inhibits testosterone synthesis in adult rats","volume":"22","author":"Sriraman","year":"2001","journal-title":"J Androl"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0100","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1073\/pnas.051632298","article-title":"Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents","volume":"98","author":"Trbovich","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0105","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1210\/en.140.6.2819","article-title":"Mullerian Inhibiting Substance type II receptor expression and function in purified rat Leydig cells","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/jc.75.3.911","article-title":"The inhibitory effects of M\u00fcllerian Inhibiting Substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells","volume":"75","author":"Kim","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0115_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1073\/pnas.0407772101","article-title":"Endometrial cancer is a receptor mediated target for Mullerian Inhibiting Substance","volume":"102","author":"Renaud","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0115_2","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1073\/pnas.0500811102","volume":"102","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mce.2003.09.010","article-title":"Mullerian substance induces NFkB signaling in breast and prostate cancer cells","volume":"211","author":"Hoshiya","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0125","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1073\/pnas.0409709102","article-title":"Mullerian Inhibiting Substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model","volume":"102","author":"Gupta","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0130","doi-asserted-by":"crossref","first-page":"16421","DOI":"10.1073\/pnas.0508304102","article-title":"Mullerian Inhibiting Substance acts as a motor neuron survival factor in vitro","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ygyno.2010.09.017_bb0135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2007.09.010","article-title":"M\u00fcllerian Inhibiting Substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers","volume":"108","author":"Bakkum-Gamez","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2010.09.017_bb0140","first-page":"1583","article-title":"The expression of M\u00fcllerian Inhibiting Substance\/anti-M\u00fcllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia","volume":"34","author":"Song","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0145","first-page":"2101","article-title":"Human M\u00fcllerian Inhibiting Substance inhibits tumor growth in vitro and in vivo","volume":"51","author":"Chin","year":"1991","journal-title":"Can Res"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0150","first-page":"2640","article-title":"Highly purified Mullerian Inhibiting Substance inhibits ovarian cancer in vivo","volume":"8","author":"Stephen","year":"2002","journal-title":"Clin Can Res"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/aja.1001960207","article-title":"The developmental expression of four novel serine\/threonine kinase receptors homologous to the activin\/TGF-b II receptor family","volume":"196","author":"He","year":"1993","journal-title":"Dev Dyn"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0160","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1242\/dev.126.11.2551","article-title":"The type I serine\/threonine kinase receptor ActRIA (ALK 2) is required for gastrulation of the mouse embryo","volume":"26","author":"Gu","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0165","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M002704200","article-title":"Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor","author":"Gouedard","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0170","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1210\/me.15.6.936","article-title":"The serine\/threonine transmembrane receptor ALK2 mediates Mullerian Inhibiting Substance signaling","volume":"15","author":"Visser","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0175","first-page":"946","article-title":"Requirement of BMPR1a for Mullerian duct Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, and Donahoe PK. M\u00fcllerian Inhibiting Substance signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression","volume":"15","author":"Jamin","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0180","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/me.15.6.946","article-title":"Mullerian Inhibiting Substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression","volume":"15","author":"Clarke","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0185","first-page":"7083","article-title":"A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction","volume":"62","author":"Zijlstra","year":"2002","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ygyno.2010.09.017_bb0190","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1242\/dev.010504","article-title":"Chick pulmonary Wnt5a directs airway and vascular tubulogenesis","volume":"135","author":"Loscertales","year":"2008","journal-title":"Development"},{"issue":"2","key":"10.1016\/j.ygyno.2010.09.017_bb0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0022-4804(77)90202-5","article-title":"A graded organ culture assay for the detection of Mullerian Inhibiting Substance","volume":"23","author":"Donahoe","year":"1977","journal-title":"J Surg Res"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0200","doi-asserted-by":"crossref","first-page":"27973","DOI":"10.1074\/jbc.M002704200","article-title":"Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-M\u00fcllerian hormone and its type II receptor","volume":"275","author":"Gou\u00e9dard","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0205","first-page":"pe40","article-title":"Id: a target of BMP signaling","author":"Miyazono","year":"2002","journal-title":"Sci STKE"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2003.09.021","article-title":"AMH induces mesonephric cell migration in XX gonads","volume":"211","author":"Ross","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ygyno.2010.09.017_bb0215","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","article-title":"Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness","volume":"103","author":"Szotek","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"44","key":"10.1016\/j.ygyno.2010.09.017_bb0220","doi-asserted-by":"crossref","first-page":"18874","DOI":"10.1073\/pnas.1012667107","article-title":"Mullerian Inhibiting Substance preferentially inhibits stem\/cell progenitors in human ovarian cancer cell lines compared with chemotherapeutics","volume":"107","author":"Wei","year":"2010","journal-title":"PNAS"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810006979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810006979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T01:23:48Z","timestamp":1711934628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810006979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0090825810006979"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.09.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}